share_log

Illumina | 10-Q: Q3 2024 Earnings Report

Illumina | 10-Q: Q3 2024 Earnings Report

Illumina | 10-Q：2024财年三季报
美股SEC公告 ·  2024/11/07 02:29

Moomoo AI 已提取核心信息

Illumina reported Q3 2024 revenue of $1.08 billion, down 3% year-over-year, while posting net income of $705 million compared to a $754 million loss last year. The profit was largely driven by a $489 million gain from the European Commission withdrawing its previously imposed fine. Core sequencing consumables revenue increased by $46 million, though instrument sales declined 41% to $107 million.Gross margin improved to 68.9% from 61.1% in Q3 2023, benefiting from operational excellence initiatives, favorable product mix, and lower warranty costs. The company completed the spin-off of GRAIL in June 2024, retaining a 14.5% stake. Operating expenses decreased significantly to $4 million from $1.44 billion last year, primarily due to the absence of prior year's goodwill impairment charges.The company ended the quarter with $869 million in cash and issued $500 million in new term notes due 2026. The Board authorized a new $1.5 billion share repurchase program, with $1.4 billion remaining available. For the full year, management continues to focus on cost reduction initiatives while maintaining investment in high-growth areas despite ongoing macroeconomic uncertainties.
Illumina reported Q3 2024 revenue of $1.08 billion, down 3% year-over-year, while posting net income of $705 million compared to a $754 million loss last year. The profit was largely driven by a $489 million gain from the European Commission withdrawing its previously imposed fine. Core sequencing consumables revenue increased by $46 million, though instrument sales declined 41% to $107 million.Gross margin improved to 68.9% from 61.1% in Q3 2023, benefiting from operational excellence initiatives, favorable product mix, and lower warranty costs. The company completed the spin-off of GRAIL in June 2024, retaining a 14.5% stake. Operating expenses decreased significantly to $4 million from $1.44 billion last year, primarily due to the absence of prior year's goodwill impairment charges.The company ended the quarter with $869 million in cash and issued $500 million in new term notes due 2026. The Board authorized a new $1.5 billion share repurchase program, with $1.4 billion remaining available. For the full year, management continues to focus on cost reduction initiatives while maintaining investment in high-growth areas despite ongoing macroeconomic uncertainties.
Illumina报告2024年第三季度营业收入为10.8亿元，同比下降3%，同时净利润为70500万元，而去年则为75400万元的亏损。利润主要受益于欧洲委员会撤回之前实施的罚款，获得48900万元的收益。核心测序耗材营业收入增加了4600万元，尽管仪器销售下降了41%，至10700万元。毛利率从2023年第三季度的61.1%提高至68.9%，受益于运营卓越的举措、良好的产品组合和较低的保修成本。该公司于2024年6月完成了GRAIL的剥离，保留了14.5%的股份。营业费用大幅下降至400万元，去年为14.4亿元，主要是由于去年没有了商誉减值费用。公司在季度末手头现金为86900万元，并发行了50000万元的新定期票据，到期于2026年。董事会批准了一项新的15亿元股票回购计划，仍有14亿元可用。为整年，管理层继续专注于成本降低举措，同时在高增长领域保持投资，尽管面临持续的宏观经济不确定性。
Illumina报告2024年第三季度营业收入为10.8亿元，同比下降3%，同时净利润为70500万元，而去年则为75400万元的亏损。利润主要受益于欧洲委员会撤回之前实施的罚款，获得48900万元的收益。核心测序耗材营业收入增加了4600万元，尽管仪器销售下降了41%，至10700万元。毛利率从2023年第三季度的61.1%提高至68.9%，受益于运营卓越的举措、良好的产品组合和较低的保修成本。该公司于2024年6月完成了GRAIL的剥离，保留了14.5%的股份。营业费用大幅下降至400万元，去年为14.4亿元，主要是由于去年没有了商誉减值费用。公司在季度末手头现金为86900万元，并发行了50000万元的新定期票据，到期于2026年。董事会批准了一项新的15亿元股票回购计划，仍有14亿元可用。为整年，管理层继续专注于成本降低举措，同时在高增长领域保持投资，尽管面临持续的宏观经济不确定性。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Prenetics Global
    PRE
    -- 4.0000
    NeoGenomics
    NEO
    -- 9.620
    Fulgent Genetics
    FLGT
    -- 17.050
    恩佐生化
    ENZ
    -- 0.431
    Personalis
    PSNL
    -- 3.620
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日